SKBI Key Stats
- Skystar Bio - Pharmaceutical Company's CEO Discusses Q1 2013 Results - Earnings ... May 16
- Stocks Hitting 52-Week Lows Benzinga May 16
- Skystar Bio Pharmaceutical Co. (SKBI) Reports Q1 EPS of $0.09 Street Insider May 16
- Skystar Bio-Pharmaceutical Reports First Quarter 2013 Results Marketwired May 16
- SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-Q, Quarterly Report May 15
- Skystar to File Financial Results for First Quarter of 2013 on Wednesday, May 15... May 14
- Form 10 K for Skystar Bio-Pharmaceutical Company Apr 24
- Skystar Bio-Pharmaceutical Reports Fiscal Year 2012 Financial Results Marketwire Apr 2
- SKYSTAR BIO-PHARMACEUTICAL CO Files SEC form 10-K, Annual Report Apr 1
- Skystar to File Audited Financial Results for Full Fiscal Year 2012 on Monday Ap... Apr 1
SKBI Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Skystar Bio-Pharmaceutical Company is down 55.07% over the last year vs S&P 500 Total Return up 31.99%, GlaxoSmithKline up 24.60%, and Tetraphase Pharmaceuticals down 0.24%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Pro Ratings for SKBI
Pro Report PDF for SKBI
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download SKBI Pro Report PDF
Pro Strategies Featuring SKBI
Did Skystar Bio-Pharmaceutical Company make it into our Pro Portfolio Strategies?